Rigel Pharmaceuticals. has filed a patent for kinase inhibitory compounds, specifically receptor-interacting protein-1 (RIP1) kinase inhibitor compounds. These compounds can be used to treat or prevent kinase-associated diseases or conditions, particularly RIP1-associated diseases or conditions. GlobalData’s report on Rigel Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Rigel Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Rigel Pharmaceuticals's grant share as of September 2023 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230310454A1) describes a compound with a specific chemical formula and various structural features. The compound is claimed to have potential applications in the treatment of diseases involving a receptor-interacting protein-1 (RIP1) kinase. The patent claims cover different variations of the compound, including different substitutions and configurations.
The compound described in the patent has a complex chemical structure, denoted by Formula I. The patent claims cover different variations of this compound, including different substitutions and configurations. For example, the compound can have a 5-membered or 6-membered heteroaryl ring B, with one or two ring nitrogen atoms and the remainder of the ring atoms being carbon. The compound can also have different ring systems denoted by specific formulas.
The patent claims also cover specific variations of the compound, such as those where Y is O and ring B is pyrazolyl or pyridinyl. The claims further specify the possible substitutions and configurations of the compound, including the presence of halogen or C1-10aliphatic groups. The claims also cover variations where the compound has specific formulas, such as those denoted by I-1, I-2, I-3, and so on.
The patent claims not only cover the compound itself but also extend to pharmaceutical compositions containing the compound, methods of administering the compound to subjects, and methods of contacting a receptor-interacting protein-1 (RIP1) kinase with the compound. The patent also claims methods for treating diseases involving a receptor-interacting protein-1 (RIP1) kinase, such as myelodysplastic syndrome, atopic dermatitis, rheumatoid arthritis, and ankylosing spondylitis.
Overall, the patent describes a compound with potential therapeutic applications in diseases involving a receptor-interacting protein-1 (RIP1) kinase. The compound has a specific chemical formula and various structural features, and the patent claims cover different variations of the compound, as well as its pharmaceutical compositions and methods of use.
To know more about GlobalData’s detailed insights on Rigel Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
